Scarica l'app Stockscreener
1.73
0.58%
0.01
Dopo l'orario di chiusura:
1.70
-0.03
-1.73%
Precedente Chiudi:
$1.72
Aprire:
$1.78
Volume 24 ore:
680.45K
Relative Volume:
0.70
Capitalizzazione di mercato:
$244.14M
Reddito:
$15.53M
Utile/perdita netta:
$-52.71M
Rapporto P/E:
-3.4428
EPS:
-0.5025
Flusso di cassa netto:
$-59.00M
1 W Prestazione:
-1.70%
1M Prestazione:
+13.07%
6M Prestazione:
+2.98%
1 anno Prestazione:
-22.42%
Intervallo 1D:
$1.71
$1.78
Intervallo di 1 settimana:
$1.70
$1.995
Portata 52W:
$1.33
$3.10
Proqr Therapeutics N V Stock (PRQR) Company Profile
Nome
Proqr Therapeutics N V
Settore
Industria
Telefono
-
Indirizzo
-
Compare PRQR vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
1.73 | 242.73M | 15.53M | -52.71M | -59.00M | -0.5025 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-12 | Ripresa | Oppenheimer | Outperform |
| 2025-04-29 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-04-29 | Iniziato | Evercore ISI | Outperform |
| 2025-03-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-01-10 | Iniziato | Oppenheimer | Outperform |
| 2024-10-29 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-11-08 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2023-03-30 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-12-22 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2022-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2022-02-11 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| 2022-02-11 | Downgrade | Stifel | Buy → Hold |
| 2022-02-01 | Iniziato | Raymond James | Strong Buy |
| 2021-05-03 | Iniziato | Stifel | Buy |
| 2021-03-25 | Reiterato | Citigroup | Buy |
| 2020-11-03 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-03-12 | Reiterato | Chardan Capital Markets | Buy |
| 2018-12-19 | Iniziato | RBC Capital Mkts | Outperform |
| 2018-11-15 | Iniziato | Citigroup | Buy |
| 2018-09-19 | Iniziato | Evercore ISI | Outperform |
| 2017-09-26 | Reiterato | JMP Securities | Mkt Outperform |
| 2016-06-20 | Iniziato | Chardan Capital Markets | Neutral |
| 2014-10-15 | Iniziato | Deutsche Bank | Buy |
| 2014-10-13 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Proqr Therapeutics N V Borsa (PRQR) Ultime notizie
PRQR|ProQR Therapeutics NV|Price:1.720|Chg%:-0.070 - TradingKey
ProQR Therapeutics NV (PRQR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ProQR Therapeutics NV (PRQR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ProQR Therapeutics N.V. Revenue Breakdown – BMV:PRQR/N - TradingView
TradingKey - TradingKey
ProQR Therapeutics NV (PRQR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ProQR Therapeutics NV (PRQR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Privium Fund Management B.V. Increases Stake in ProQR Therapeuti - GuruFocus
Bart Filius Acquires Additional Shares in ProQR Therapeutics NV - GuruFocus
Form 4 ProQR Therapeutics N.V. For: 21 July By Investing.com - Investing.com South Africa
Proqr Therapeutics N.v. Insider Bought Shares Worth $257,925, According to a Recent SEC Filing - marketscreener.com
ProQR Therapeutics (PRQR) director purchases 150,000 Ordinary Shares - Stock Titan
ProQR Therapeutics (NASDAQ:PRQR) Stock Passes Above 50-Day Moving AverageHere's Why - MarketBeat
ProQR Therapeutics Virtual Investor Event Transcript - GuruFocus
ProQR Therapeutics (PRQR) Gains 1.8% as Shares Test Key Resistance Near $1.78Entry Point Alerts - dars.gov.et
ProQR Therapeutics N.V. SEC Filing (Jul 16, 2026) - Stock Titan
ProQR Therapeutics (NASDAQ: PRQR) details 3.0M-share resale and balance sheet - Stock Titan
Aescap group and Patrick Krol report ProQR (PRQR) shareholdings - Stock Titan
Insider Buying: CEO de Boer Daniel Anton Acquires 150,000 Shares of ProQR Therapeutics NV - GuruFocus
ProQR Therapeutics (NASDAQ:PRQR) CEO Boer Daniel Anton De Buys 150,000 Shares - MarketBeat
ProQR (PRQR) CEO lifts stake to 300,000 shares - Stock Titan
ProQR Therapeutics (PRQR) Faces Pressure at $1.73 After 1.7% DeclineSocial Sentiment - dars.gov.et
ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
ProQR (PRQR) CEO Daniel de Boer purchases 150,000 Ordinary Shares at $1.59 - Stock Titan
ProQR Therapeutics files prospectus for 3.03M share offering - scanx.trade
ProQR Therapeutics (PRQR) registers 3.03M shares for resale on Nasdaq - Stock Titan
ProQR prices $50M stock offering; secures $9.2M investment from Eli Lilly - MSN
ProQR Therapeutics: Human NTCP Data Strengthens The Axiomer Thesis (NASDAQ:PRQR) - Seeking Alpha
ProQR posts early-stage trial data for liver disease candidate - MSN
Insider Buying: ProQR Therapeutics Independent Non-Executive Director Bought €231k Of Shares - simplywall.st
PRQRProQR Therapeutics N.V Options - Finviz
PRQR Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Advances PipelineEarnings Preview - dars.gov.et
Bart Filius Acquires 150,000 Shares of ProQR Therapeutics NV - GuruFocus
Form 13D/A ProQR Therapeutics N.V. For: 30 June By Investing.com - Investing.com South Africa
Van Herk group reports 10.9% ProQR (PRQR) ownership after share issuances - Stock Titan
ProQR (PRQR) director receives 14,595-share option grant at $1.42 strike - Stock Titan
Director Bart Filius buys 150,000 ProQR (PRQR) Ordinary Shares in open market - Stock Titan
ProQR Therapeutics N.V. Actuals & Estimates (TRADEGATE:0PQ) - TradingView
0PQ Forecast — Price Target — Prediction for 2027 - TradingView
PRQR Maintained by Evercore ISI Group -- Price Target Raised to $6.00 - GuruFocus
Small-cap ProQR Therapeutics secures funding from Eli Lilly on early trial success - MSN
ProQR Raises $59 Million in Equity Offering and Eli Lilly Private Placement - The Globe and Mail
ProQR Therapeutics (NASDAQ: PRQR) raises capital; Lilly to purchase 5.1M shares - Stock Titan
PRQR Maintains Buy Rating by Jones Trading -- Price Target Lowered to $10.00 - GuruFocus
PRQR Maintained by Chardan Capital -- Price Target Lowered to $3 - GuruFocus
ProQR Therapeutics N.V. Actuals & Estimates (DUS:0PQ) - TradingView
ProQR Therapeutics N.V. Actuals & Estimates (NASDAQ:PRQR) - TradingView
Chardan Research Adjusts ProQR Therapeutics Price Target to $3 From $4, Maintains Buy Rating - marketscreener.com
Small-Cap ProQR Therapeutics Secures Funding From Eli Lilly On Early Trial Success - Sahm
ProQR (PRQR) prices share offering and Eli Lilly private placement - Stock Titan
Price to book forward of ProQR Therapeutics N.V. – NASDAQ:PRQR - TradingView
Proqr Therapeutics N V Azioni (PRQR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):